What Is Hospice Care?
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in patients with...
- The SELECT trial followed participants for an average of 3.4 years.
- Importantly, the study also observed a greater reduction in body weight in the semaglutide group (an average of 15% weight loss) and improvements in other cardiovascular risk factors...
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in patients with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo.The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed a statistically notable, though modest, increase in risk within the treatment group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and Data Breakdown
The SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of cardiovascular death,nonfatal myocardial infarction,or nonfatal stroke occurred in 6.5% of patients receiving semaglutide versus 5.8% of those receiving placebo. This translates to a hazard ratio of 1.13, indicating a 13% increased risk. While this difference is statistically significant, it’s crucial to understand the absolute risk increase is relatively small.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Cardiovascular Death | 1.5 | 1.2 | 1.26 |
| Nonfatal Myocardial Infarction | 2.5 | 2.2 | 1.16 |
| Nonfatal Stroke | 2.5 | 2.4 | 1.06 |
| composite Outcome (CV Death, MI, Stroke) | 6.5 | 5.8 | 1.13 |
Importantly, the study also observed a greater reduction in body weight in the semaglutide group (an average of 15% weight loss) and improvements in other cardiovascular risk factors like blood pressure and cholesterol. Though, these benefits did not outweigh the observed increase in cardiovascular events.
Who is Affected? Understanding the Patient Population
The SELECT trial specifically enrolled individuals with a history of established cardiovascular disease – meaning they had previously experienced a heart attack, stroke, or peripheral artery disease – *and* obesity.This is a critical distinction. The findings do *not* necessarily apply to individuals using semaglutide for weight loss without pre-existing cardiovascular conditions. Though, it raises concerns about the safety profile of the drug in a vulnerable population and warrants further investigation in other patient groups.
The average age of participants was 61, and approximately 40% were women. This demographic information is important for understanding the generalizability of the findings.
what Does This Mean? Implications for Patients and Physicians
These results necessitate a more cautious approach to prescribing semaglutide, notably for patients with established cardiovascular disease. Doctors should carefully weigh the potential benefits of weight loss against the potential cardiovascular risks, engaging in a thorough discussion with their patients about these findings. It’s crucial to emphasize that this is a relative risk increase, and the absolute risk remains relatively low.
Further research is needed to understand the mechanisms driving this increased risk.Possible explanations include the rapid weight loss induced by semaglutide,